Early Donanemab Start Adds One-Third More Lifetime Value in USC Microsimulation

The October 7 Alzheimer's & Dementia study used a dynamic microsimulation calibrated to national surveys and TRAILBLAZER-ALZ 2 trial data. Researchers compared no treatment, trial-timed donanemab, and treatment initiated two years sooner while still post-symptom onset. All projections applied a 29% slowing of progression observed at 18 months and excluded drug or monitoring costs. Earlier start increased time living independently and reduced years with severe dementia beyond the 0.3-year survival gain seen in standard timing.

The 3.5-year average diagnostic lag after symptoms creates a measurable window for intervention. Blood-based biomarkers cleared by FDA in 2025 and digital cognitive tools could close this gap, yet current coverage policies and specialist access barriers limit uptake. The model shows roughly half the value accrues as quality-of-life gains, with the remainder split between unpaid caregiver time and Medicaid offsets, illustrating how earlier amyloid clearance alters downstream resource use across payers and families.

Broader patterns from prior disease-modifying therapies suggest that shifting diagnosis earlier requires coordinated screening infrastructure rather than isolated drug approvals. Without such systems, the one-third incremental benefit remains theoretical. Next steps include real-world evidence from ongoing registries to test whether the modeled 13% Medicaid reduction materializes once blood tests scale.

Policy decisions on coverage and screening reimbursement will determine whether the projected societal returns are realized within the next five years.